Loading
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Previous close
$114.79
+$0.755 · +0.66%
Regular session · ET · Market data may be delayed.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Day range
Current $114.79
52-week range
Current $114.79
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
31
Expensive
Sentiment
55
Mixed
Risk
35
Moderate Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Day range
Current $114.79
52-week range
Current $114.79
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | 50.76M EUR | 45.52M EUR |
| Gross profit | — | — | — | −50.76M EUR | −45.52M EUR |
| Research and development | 177.76M EUR | 146.53M EUR | 103.18M EUR | 48.3M EUR | 47.78M EUR |
| Selling, general, and administrative | 72.87M EUR | 38.9M EUR | 28.82M EUR | 7.49M EUR | 5.58M EUR |
| Operating expenses | 246.06M EUR | 172.98M EUR | 127.38M EUR | 14.07M EUR | −4.12M EUR |
| Interest income | 5.75M EUR | 8.96M EUR | 2.77M EUR | — | — |
| Interest expense | 28.48M EUR | 12.43M EUR | 13.83M EUR | 6.94M EUR | 3.56M EUR |
| Depreciation and amortization | 1.07M EUR | 1.1M EUR | 707K EUR | 485K EUR | 302K EUR |
| Operating income | −246.06M EUR | −172.98M EUR | −127.38M EUR | −64.84M EUR | −41.4M EUR |
| Net income | −336.1M EUR | −176.24M EUR | −147.74M EUR | −60.74M EUR | −42.45M EUR |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$152.71
33.03% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB54.72M0.52%10.72B USD0.44%$211.92-0.88%
Schwab International Equity ETFSCHF19.74M0.03%69.05B USD0.03%$28.58+0.42%
Goldman Sachs Hedge Industry VIP ETFGVIP11.45M1.98%565.49M USD0.45%$173.49+1.49%
Alger 35 ETFATFV7.14M1.49%257.79M USD0.56%$40.1106+0.71%
State Street SPDR Portfolio Developed World ex-US ETFSPDW7.06M0.02%42.37B USD0.03%$52.31+0.40%
Vanguard Total International Stock ETFVXUS3.54M0.00%646.2B USD0.05%$88.41+0.50%
Vanguard FTSE Developed Markets ETFVEA2.35M0.00%315B USD0.03%$73.76+0.44%
Fidelity Nasdaq Composite Index ETFONEQ1.67M0.02%10.35B USD0.21%$104.46-0.29%iShares Biotechnology ETFIBBSchwab International Equity ETFSCHFGoldman Sachs Hedge Industry VIP ETFGVIPAlger 35 ETFATFVState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAFidelity Nasdaq Composite Index ETFONEQAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
